Nephrogenic systemic fibrosis

Nephrogenic systemic fibrosis, initially called nephrogenic fibrosing dermopathy, has been strongly linked to exposure to gadolinium-based contrast media used in magnetic resonance imaging in patients with renal insufficiency. This review discusses recent advances in our understanding of the pathophysiology and clinical approach to patients with chronic kidney disease who require diagnostic imaging with gadolinium-based contrast media.

[1]  P. Leboit,et al.  Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. , 2011, Journal of the American Academy of Dermatology.

[2]  J. Collins,et al.  Detection of renal dysfunction by point-of-care creatinine testing in patients undergoing peripheral MR angiography. , 2011, AJR. American journal of roentgenology.

[3]  A. Abu-Alfa,et al.  Nephrogenic systemic fibrosis and gadolinium-based contrast agents. , 2011, Advances in chronic kidney disease.

[4]  Francisca Kartono,et al.  Findings of osseous sclerotic bodies: a unique sequence of cutaneous bone formation in nephrogenic systemic fibrosis , 2011, Journal of cutaneous pathology.

[5]  C. Robic,et al.  Clinical, Biological, and Skin Histopathologic Effects of Ionic Macrocyclic and Nonionic Linear Gadolinium Chelates in a Rat Model of Nephrogenic Systemic Fibrosis , 2011, Investigative radiology.

[6]  S. George,et al.  Synchrotron X‐ray analyses demonstrate phosphate‐bound gadolinium in skin in nephrogenic systemic fibrosis , 2010, The British journal of dermatology.

[7]  S. Morcos,et al.  Nephrogenic Gadolinium Biodistribution and Skin Cellularity Following a Single Injection of Omniscan in the Rat , 2010, Investigative radiology.

[8]  Diego R. Martín,et al.  Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast‐enhanced MRI protocols , 2010, Journal of magnetic resonance imaging : JMRI.

[9]  Kui Wang,et al.  Gadolinium-containing bioparticles as an active entity to promote cell cycle progression in mouse embryo fibroblast NIH3T3 cells , 2010, JBIC Journal of Biological Inorganic Chemistry.

[10]  J. Weinreb,et al.  Gadolinium‐based contrast agents and nephrogenic systemic fibrosis: Why did it happen and what have we learned? , 2009, Journal of magnetic resonance imaging : JMRI.

[11]  S. Saini,et al.  Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients , 2009, Journal of magnetic resonance imaging : JMRI.

[12]  Diego R. Martín,et al.  Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities. , 2009, Radiology.

[13]  R. Gomer,et al.  Gadolinium‐containing magnetic resonance image contrast agent promotes fibrocyte differentiation , 2009, Journal of magnetic resonance imaging : JMRI.

[14]  S. Jimenez,et al.  Mechanism of NSF: New evidence challenging the prevailing theory , 2009, Journal of magnetic resonance imaging : JMRI.

[15]  P. Altmeyer,et al.  Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options. , 2009, Journal of the American Academy of Dermatology.

[16]  J. Sliwa,et al.  Rehabilitation in Nephrogenic Systemic Fibrosis , 2009, PM & R : the journal of injury, function, and rehabilitation.

[17]  J. Bhawan,et al.  Sclerotic bodies in nephrogenic systemic fibrosis: a new histopathologic finding , 2009, Journal of cutaneous pathology.

[18]  T. Steger-Hartmann,et al.  Impact of Renal Impairment on Long-Term Retention of Gadolinium in the Rodent Skin Following the Administration of Gadolinium-Based Contrast Agents , 2009, Investigative radiology.

[19]  D. Løvhaug,et al.  Effects of gadolinium contrast agents in naïve and nephrectomized rats: Relevance to nephrogenic systemic fibrosis , 2009, Acta radiologica.

[20]  S. Lai,et al.  Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases. , 2009, Radiology.

[21]  E. Lancelot,et al.  Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. , 2008, Toxicology.

[22]  M. Edward,et al.  Gadodiamide contrast agent ‘activates’ fibroblasts: a possible cause of nephrogenic systemic fibrosis , 2008, The Journal of pathology.

[23]  J. Topf,et al.  Nephrogenic Fibrosing Dermopathy , 2008, TheScientificWorldJournal.

[24]  H. Thomsen,et al.  High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent , 2008, Investigative radiology.

[25]  S. Cowper,et al.  NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment , 2008, Seminars in dialysis.

[26]  A. Abu-Alfa.  The impact of NSF on the care of patients with kidney disease. , 2008, Journal of the American College of Radiology : JACR.

[27]  R. Bucala.  Circulating fibrocytes: cellular basis for NSF. , 2008, Journal of the American College of Radiology : JACR.

[28]  R. Woolson,et al.  Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  L. Skov,et al.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  A. Jardine,et al.  Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. , 2007, Radiology.

[31]  L. Chibnik,et al.  Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. , 2007, Arthritis and rheumatism.

[32]  D. Fiorentino,et al.  Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. , 2007, Archives of dermatology.

[33]  B. Şahın,et al.  Autoantibody Profile in Systemic Sclerosis as a Marker for Esophageal and Other Organ Involvement in Turkish Populations , 2007, Digestive Diseases and Sciences.

[34]  A. Duncan.  Commentary on "Reflux testing and imaging for endovenous ablation". , 2007, Perspectives in vascular surgery and endovascular therapy.

[35]  E. Kanal,et al.  Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. , 2007, Radiology.

[36]  S. Cowper,et al.  Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[37]  S. Cowper,et al.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[38]  S. Cowper,et al.  Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[39]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[40]  M. Pittelkow,et al.  Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. , 2006, Annals of internal medicine.

[41]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  Shawn Cowper,et al.  Circulating fibrocytes: collagen-secreting cells of the peripheral blood. , 2004, The international journal of biochemistry & cell biology.

[43]  S. Cowper.  Nephrogenic fibrosing dermopathy: the first 6 years , 2003, Current opinion in rheumatology.

[44]  R. Bucala,et al.  Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. , 2003, The American Journal of dermatopathology.

[45]  W. Ting,et al.  Nephrogenic fibrosing dermopathy with systemic involvement. , 2003, Archives of dermatology.

[46]  P. Leboit.  What nephrogenic fibrosing dermopathy might be. , 2003, Archives of dermatology.

[47]  N. Liégeois,et al.  Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. , 2003, Journal of the American Academy of Dermatology.

[48]  P. Leboit,et al.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.

[49]  H. Thomsen,et al.  Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.

[50]  J. Frisoli,et al.  Nephrotoxicity of high‐dose gadolinium compared with iodinated contrast , 1996, Journal of magnetic resonance imaging : JMRI.

[51]  R. Bucala,et al.  Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair , 1994, Molecular medicine.